Immune-Onc: Immune-Onc Therapeutics, Inc.: Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
- IO-202, in combination with azacitidine, has demonstrated clinically meaningful benefit for frontline CMML patients - - IO-202 is a first-in-class humanized IgG1 monoclonal antibody targeting Le...
Read full article »
Immune-Onc is a California-based biotechnology company that researches and develops immunotherapies for the treatment of cancer and solid tumors.
Read more